Answers are grounded in this paper and cite their sources.
Randomised, double-blind, crossover trial to confirm bioequivalence of somapacitan, a long-acting growth hormone (GH), in 5 mg/1.5 mL and 10 mg/1.5 mL strengths in equimolar doses.
No takes yet. Share an insight, caveat, or question.
Dombernowsky et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: